2018
Persistence of abnormalities in white matter in children with type 1 diabetes
Fox LA, Hershey T, Mauras N, Arbeláez AM, Tamborlane WV, Buckingham B, Tsalikian E, Englert K, Raman M, Jo B, Shen H, Reiss A, Mazaika P, for the Diabetes Research in Children Network (DirecNet). Persistence of abnormalities in white matter in children with type 1 diabetes. Diabetologia 2018, 61: 1538-1547. PMID: 29654376, PMCID: PMC5991628, DOI: 10.1007/s00125-018-4610-6.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkersBlood GlucoseCase-Control StudiesChildChild DevelopmentChild, PreschoolCognitive DysfunctionDiabetes Mellitus, Type 1Diffusion Tensor ImagingFemaleGlycated HemoglobinHumansLeukoencephalopathiesLongitudinal StudiesMagnetic Resonance ImagingMalePrognosisRisk FactorsTime FactorsUnited StatesConceptsType 1 diabetesNon-diabetic childrenWhite matter microstructureWhite matterAltered white matter developmentContinuous glucose monitoring (CGM) profilesFractional anisotropyConclusions/interpretationThese resultsPersistence of abnormalitiesLongitudinal observational studyWhite matter growthYoung childrenWhite matter developmentMild cognitive deficitsHigher fractional anisotropyDiabetes groupClinical centersMethodsOne hundredObservational studyDiabetesInterpretationThese resultsCognitive deficitsHyperglycaemiaDiabetes researchAdverse effects
2016
Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care 2016, 39: 555-562. PMID: 26884472, PMCID: PMC4806770, DOI: 10.2337/dc15-1606.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntranasalAdolescentBlood GlucoseChildChild, PreschoolCohort StudiesCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugDouble-Blind MethodDrug-Related Side Effects and Adverse ReactionsFemaleGlucagonHumansHypoglycemiaInjections, IntramuscularInsulinMaleNauseaPowdersConceptsIntramuscular glucagonType 1 diabetesIntranasal dosesIntranasal glucagonYounger cohortsWeight-based doseMin of dosingTreatment of hypoglycemiaDose-response relationshipTransient nauseaDl riseSevere hypoglycemiaGlucagon levelsIntranasal doseClinical centersPlasma glucosePharmacodynamic studiesHospital settingGlucagon preparationPotential efficacyGlucagonType 1Adverse effectsCohortAge range
2012
The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA. The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin. Diabetes Care 2012, 35: 690-692. PMID: 22374642, PMCID: PMC3308292, DOI: 10.2337/dc11-0732.Peer-Reviewed Original ResearchConceptsType 1 diabetesDetemir insulinInsulin analoguesInsulin pharmacodynamicsRapid-acting insulin analoguesRapid-acting insulinTime-action profileEuglycemic glucose clampCommon regimenRandomized studyDaily injectionsUnits/Glucose clampInsulin actionSame syringePharmacodynamicsAspartInsulinDiabetesRandom orderAdverse effectsSeparate injectionsAction studiesInjectionMixed injection